DLG5与34βE12在乳腺癌中表达的相关性及临床意义  

Relationship and clinical significance of DLG5 and 34βE12 in breast cancer

作　　者：刘洁 李娟[1] 李萍萍 周灿 刘培军 Liu Jie;Li Juan;Li Pingping;Zhou Can;Liu Peijun(Center for Translational Medicine;Department of Breast Surgery,the First Affiliated Hospital of Xi＇an Jiaotong University,Shaanxi Xi＇an 710061,China.)

机构地区：[1]西安交通大学第一附属医院转化医学中心,陕西西安710061 [2]西安交通大学第一附属医院乳腺外科,陕西西安710061

出　　处：《现代肿瘤医学》2018年第20期3224-3228,共5页Journal of Modern Oncology

基　　金：国家自然科学基金青年基金(编号:81703002;81702631;81502620)

摘　　要：目的:探讨细胞极性蛋白DLG5与高分子量角蛋白(34βE12)在乳腺癌中表达的相关性,阐明其在乳腺癌临床诊断中的作用。方法:收集乳腺癌组织,通过免疫组织化学(immunohistochemistry,IHC)分析DLG5的表达情况,以及其与34βE12表达的相关性。利用慢病毒技术敲低DLG5的表达后,Western blot检测DLG5与34βE12的表达。结果:DLG5的表达随乳腺癌恶性程度增加而降低,与雌激素受体/孕激素受体(ER/PR)、34βE12的表达呈现正相关性。在乳腺上皮细胞MCF10A中,敲低DLG5表达后,34βE12的表达显著降低。结论:在乳腺癌中,DLG5可以用于早期诊断、恶性程度判定,并且可以作为ER/PR阳性乳腺癌治疗及预测预后的潜在生物标志物。Objective：To investigate the role of DLG5 in clinical diagnosis of breast cancer by studying the rela-tionship between DLG5 and 34βE12. Methods ：The expression of DLG5 in different stages and different 34βE12 status breast cancer were measured by immunohistochemistry technical analysis. Inmmnoblotting analysis of the relation-ship between DLG5 and 3413E12 after knockdown of DLG5 expression was done by lentivirus-mediated shRNA inter-ference. Results ：DLG5 was highly expressed in low-grade breast cancer, but its expression was reduced or lost in high-grade breast cancer. DLG5 expression showed a positive correlation with ER/PR and 34βE12 status in breast cancer. Knockdown of DLG5 expression inhibited 34βE12 expression in MCF10A cells. Conclusion： DLG5 can be used in clinical diagnosis of breast cancer and might be a biomarker of ER/PR positive breast cancer treatment and prognosis.

关 键 词：乳腺癌 细胞极性蛋白DLG5 34ΒE12 

分 类 号：R737.9[医药卫生—肿瘤]